Recent reports suggest there are an increasing number of high-impact research studies that cannot be replicated by other scientists. These reports have raised concerns about incorrectly or insufficiently characterized antibodies.
As a company rooted in science, we are troubled by these reports.
Our approach has always been to produce and rigorously validate our products in-house. This ensures they will work in your experiments and be worthy of the important experiments they support.
We think our approach is part of an achievable solution to research reproducibility that focuses on three elements: materials, methods and mentoring.
Every CST antibody undergoes rigorous application-specific validation testing customized according to the target and needs of the individual antibody. Below is a sampling of the methods we may employ to ensure our antibodies perform as expected.
Side-by-side comparison of lots to ensures lot-to-lot consistency.
Western blot analysis of HeLa cells, untreated or treated with IFN-α, comparing lots 1, 2, 3 and 8 of Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145. Note: Signal remains consistent from lot to lot. (Recommended dilution for western blot was changed to 1:2000 with release of lot 3.)
Antibody performance is assessed in relevant mouse models of cancer.
Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060: IHC analysis of paraffin-embedded WT (left) and PTEN (-/-) (right) mouse prostate using #4060. Tissue courtesy of Dr. David Guertin, The Whitehead Institute for Biomedical Research, Cambridge, MA.